Focused On-demand Library for EKC/KEOPS complex subunit GON7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BXV9

UPID:

GON7_HUMAN

Alternative names:

Alternative UPACC:

Q9BXV9; Q0D2N1; Q0P6C4; Q3B7W5

Background:

The EKC/KEOPS complex subunit GON7 plays a crucial role in protein synthesis and cellular health by participating in the modification of transfer RNAs (tRNAs). Specifically, it is involved in the formation of a threonylcarbamoyl group on adenosine at position 37 in tRNAs that read codons beginning with adenine. This modification is essential for the proper decoding of mRNA and the synthesis of proteins.

Therapeutic significance:

GON7's association with Galloway-Mowat syndrome 9, a severe renal-neurological disorder, underscores its potential as a target for therapeutic intervention. Understanding the role of EKC/KEOPS complex subunit GON7 could open doors to potential therapeutic strategies for this devastating condition, offering hope for affected individuals and their families.